Siponimod reduces risk of disability progression by 21%

[MSUK]

Scientists who conducted a randomised, double-blind, placebo-controlled, phase III study, evaluating siponimod versus a placebo in patients with secondary progressive multiple sclerosis (SPMS) have managed to reduce the risk of disability progression by 21 per cent, over a three month period...Read more - http://www.ms-uk.org/siponimod-reduces- ... ent-090517

[NHE]

Scientists who conducted a randomised, double-blind, placebo-controlled, phase III study, evaluating siponimod versus a placebo in patients with secondary progressive multiple sclerosis (SPMS) have managed to reduce the risk of disability progression by 21 per cent.

That sounds good. However, it's a relative percentage reduction. The actual data plot doesn't look that impressive.

[Zyklon]

I agree with NHE. Not much improvement and lots of possible side effects.